AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AZN · NYSE · Drug Manufacturers - General

AstraZeneca (ADR) (AZN)

Develops oncology-led medicines spanning rare diseases, cardiovascular care, metabolism, respiratory disease, and immunology.

$168.50

vs last close+0.40 (+0.24%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	11,492	12,024	12,679	12,938	13,565	14,891	13,588	14,457	15,191	15,503	15,288	15,384
Cost of revenue	2,095	2,308	2,218	2,183	3,081	2,725	2,241	2,473	2,801	3,118	2,678	2,523
Gross profit	9,397	9,716	10,461	10,755	10,484	12,166	11,347	11,984	12,390	12,385	12,610	12,861
	7,443	8,482	7,346	8,009	8,378	10,130	7,673	8,476	8,807	9,407	8,364	9,697
Research & development	2,584	3,073	2,783	3,008	3,115	4,677	3,159	3,548	3,663	3,862	3,492	4,053
	4,929	5,516	4,630	5,061	5,288	5,553	4,627	5,007	5,233	5,645	5,061	5,796
Selling & marketing	129	145	135	132	145	143	135	143	148	153	141	145
General & administrative	4,800	5,371	4,495	4,929	5,143	5,410	4,492	4,864	5,085	5,492	4,920	5,651
Other expenses	−70	−107	−67	−60	−25	−100	−113	−79	−89	−100	−189	−152
Operating income	1,954	1,234	3,115	2,746	2,106	2,036	3,674	3,508	3,583	2,978	4,246	3,164
	−302	−337	−315	−349	−278	−370	−272	−381	−339	−349	−332	−365
Interest income	101	108	111	100	183	64	84	68	85	123	73	80
Interest expense	392	445	413	443	457	429	349	439	434	472	393	435
Other non-operating income	−90	−108	−98	−94	−179	−59	−77	−58	−95	−123	−61	−70
Income before tax	1,652	897	2,800	2,397	1,828	1,666	3,402	3,127	3,244	2,629	3,914	2,799
Income tax expense	274	−62	620	469	395	166	481	679	709	300	833	291
Net income from continuing operations	1,378	959	2,180	1,928	1,433	1,500	2,921	2,448	2,535	2,329	3,081	2,508
Net income	1,374	960	2,179	1,927	1,429	1,500	2,916	2,450	2,533	2,326	3,080	2,507
EPS, basic	$0.89	$0.61	$1.41	$0.62	$0.92	$0.97	$1.88	$1.58	$1.62	$1.51	$1.99	$1.60
EPS, diluted	$0.88	$0.61	$1.40	$0.62	$0.91	$0.96	$1.87	$1.57	$1.62	$1.48	$1.97	$1.59
Weighted average shares, basic	1,549	1,549	1,549	1,554	1,554	1,550	1,550	1,550	1,561	1,550	1,549	1,551
Weighted average shares, diluted	1,560	1,561	1,560	1,560	1,560	1,562	1,561	1,559	1,561	1,562	1,561	1,560
EBITDA	3,326	2,669	4,468	4,119	4,102	2,809	5,035	4,955	5,227	4,612	5,673	5,163
Depreciation & amortization	1,282	1,327	1,255	1,279	1,817	714	1,284	1,389	1,549	1,511	1,366	1,929
EBIT	2,044	1,342	3,213	2,840	2,285	2,095	3,751	3,566	3,678	3,101	4,307	3,234